Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results
Portfolio Pulse from
Theriva Biologics has completed enrollment in its VIRAGE Phase 2b clinical trial for VCN-01, targeting metastatic pancreatic ductal adenocarcinoma. Topline data is anticipated in Q2 2025.
March 06, 2025 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Theriva Biologics has completed enrollment in its VIRAGE Phase 2b trial for VCN-01, targeting metastatic PDAC, with results expected in Q2 2025.
The completion of enrollment in a clinical trial is a significant milestone for biotech companies, often leading to positive investor sentiment. The anticipation of topline data in Q2 2025 could drive interest and potential stock price appreciation in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100